Buscar

01/09/2022 Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients
Pinana, JL, Rodriguez-Belenguer, P, Caballero, D, Martino, R, Lopez-Corral, L, Terol, MJ, Vazquez, L, Calabuig, M, Sanz-Linares, G, Marin-Jimenez, F, Alonso, C, Montoro, J, Ferrer, E, Facal, A, Pascual, MJ, Rodriguez-Fernandez, A, Olave, MT, Cascales-Hernandez, A, Gago, B, Hernandez-Rivas, JA, Villalon, L, Corona, M, Roldan-Perez, A, Ribes-Amoros, J, Gonzalez-Santillana, C, Garcia-Sanz, R, Navarro, D, Serrano-Lopez, AJ, Cedillo, A, Soria-Olivas, E, Sureda, A, Solano, C. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients. ANNALS OF HEMATOLOGY. 2022; 101(9)DOI:10.1007/s00277-022-04906-8. PMID:35780254. IF:3.500(Q2/5D).
01/08/2022 Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan
Guijarro, F, Bataller, A, Diaz-Beya, M, Garrido, A, Coll-Ferra, C, Vives, S, Salamero, O, Valcarcel, D, Tormo, M, Arnan, M, Sampol, A, Castano-Diez, S, Martinez, C, Suarez-Lledo, M, Fernandez-Aviles, F, Hernandez-Boluda, JC, Ribera, JM, Rovira, M, Brunet, S, Sierra, J, Esteve, J. Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan. BONE MARROW TRANSPLANTATION. 2022; 57(8)DOI:10.1038/s41409-022-01703-9. PMID:35643942. IF:4.800(Q1/2D).
01/08/2022 Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas
Moreno, DF, Clapes, V, Soler, JA, Gonzalez-Montes, Y, Gironella, M, Motllo, C, Granell, M, Abella, E, Garcia-Pintos, M, Garcia-Guinon, A, Cabezudo, E, Blade, J, Rosinol, L. Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas. Clinical Lymphoma Myeloma & Leukemia. 2022; 22(8)DOI:10.1016/j.clml.2022.04.014. PMID:35610120. IF:2.700(Q3/7D).
01/08/2022 TP53 Abnormalities Are Underlying the Poor Outcome Associated with Chromothripsis in Chronic Lymphocytic Leukemia Patients with Complex Karyotype
Ramos-Campoy, S, Puiggros, A, Kamaso, J, Bea, S, Bougeon, S, Larrayoz, MJ, Costa, D, Parker, H, Rigolin, GM, Blanco, ML, Collado, R, Ancin, I, Salgado, R, Moro-Garcia, MA, Baumann, T, Gimeno, E, Moreno, C, Salido, M, Calvo, X, Calasanz, MJ, Cuneo, A, Nguyen-Khac, F, Oscier, D, Haferlach, C, Strefford, JC, Schoumans, J, Espinet, B. TP53 Abnormalities Are Underlying the Poor Outcome Associated with Chromothripsis in Chronic Lymphocytic Leukemia Patients with Complex Karyotype. Cancers. 2022; 14(15)DOI:10.3390/cancers14153715. PMID:35954380. IF:5.200(Q2/3D).